ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on June 18, 2018. The report details the closing of an additional share sale related to a follow-on offering that initially closed on June 12, 2018.
Key Financial Metrics
- Transaction Type: Exercise of underwriters' full over-allotment option.
- Shares Sold: 1,255,230 shares of common stock.
- Gross Proceeds: Approximately $6.0 million.
- Offering Price: $4.78 per share.
- Net Proceeds: Not specified in this filing (gross proceeds are before underwriting discounts and commissions).
Material Changes
The primary material event is the increase in outstanding common stock and capital raised through the full exercise of the over-allotment option. This follows the initial closing of 8,368,200 shares on June 12, 2018. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
This filing does not contain updated financial guidance, management outlook, or specific risk factors beyond the standard disclosure of the capital raise. The filing notes the company is an emerging growth company.
Investor Verification Checklist
- Verify the total number of shares outstanding post-transaction (initial 8,368,200 + over-allotment 1,255,230).
- Review the underwriting agreement to determine the exact underwriting discounts and commissions to calculate net proceeds.
- Confirm the use of proceeds as disclosed in the related prospectus or earlier filings.
- Check for any dilution impact on existing shareholders.